Phase II sequential treatment trial of single agent Nivolumab, then combination Ipilumumab + Nivolumab in metastic or unresectable non-clear cell renal cell carcinoma (ANZUP1602). UNISoN.

Pook, David (Primary Chief Investigator (PCI))

Medicine Monash Health

Project: Research

Project Description

NMA HREC Ref number: HREC/17/HAWKE/261
NMA SSA Ref number: SSA/18/MonH/15
Monash Health Ref: RES-19-0000-018X

Status	Finished
Effective start/end date	18/10/18 → 17/10/23